Effect of Resveratrol and Pharmacist Intervention on Diabetes Mellitus and Its Neuropathic Complication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-05

Study Completion Date

2022-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Management of symptoms associated with diabetic neuropathy is a difficult issue for clinicians since it usually does not respond to standard analgesics. Resveratrol is a naturally occurring plant-derived, polyphenolic compound, it exerts pleiotropic activity. The investigators believed that the implementation of multidisciplinary approaches including pharmacotherapy and provision of healthcare professional services such as pharmacist intervention are needed for alleviation of diabetic associated neuropathy.Therefore, the hypothesis of the present protocol is that the administration of resveratrol and/or provision of pharmaceutical care in patients with diabetic neuropathy might be of value in improving quality of life and managing diabetic neuropathic pain.The study is designed as a four-arm randomized, placebo-controlled clinical trial. Group one will be given only conventional hypoglycemic drugs. Group two patients will receive conventional hypoglycemic drugs accompanied by pharmacist interventions. Group three; patients will receive resveratrol 500 mg orally once daily after meals for three months, in addition to their regular hypoglycemic drugs. Group four; patients will receive resveratrol 500 mg orally once daily after meals along with their regular hypoglycemic drugs for a period of three months, accompanied by pharmacist interventions. Neuropathic pain will be measured by various neuropathic pain assessment tools. Nerve conduction studies will be performed to assess the effect of interventional therapy. The expected outcome will be the improvement of diabetic neuropathy associated symptoms along with glycemic status.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

NCT02114892

Metabolic Syndrome X

COMPLETED PHASE2

Resveratrol and First-degree Relatives of Type 2 Diabetic Patients

NCT02129595

Pre-diabetes

COMPLETED NA

Resveratrol and Type 2 Diabetes

NCT01638780

Type 2 Diabetes

UNKNOWN NA

Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus

NCT02549924

Type 2 Diabetes Mellitus

TERMINATED PHASE2

Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus

NCT01881347

Diabetes Mellitus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Diabetic neuropathy is the most common microvascular complication of diabetes, resulting from prolonged periods of hyperglycemia, damaging fragile nerve fibers and the walls of their blood vessels.
* Despite clinical developments in the treatment of diabetes complications, especially diabetic neuropathy, it still remains a clinical challenge with no effective solution.
* Conventional therapies such as anti-epileptics, opioid analgesics, and antidepressants for the treatment of neuropathic pain are quite challenging due to their serious adverse effects.
* There is a need to investigate novel effective and safe options.
* Recently, polyphenols have also been introduced as potential neuroprotective agents in diabetes.
* Alleviation of the symptoms associated with diabetic neuropathy and exerting preventive measures to halt the emergence of neuropathy complications are crucial priorities, and this requires multidisciplinary approaches including pharmacotherapy and provision of healthcare professional services such as pharmacist intervention.
* Aim of the study: to evaluate the effects of resveratrol and pharmaceutical care on the severity of diabetic neuropathy and improvement in the quality of life of diabetic patients.
* Study design: four-arm randomized, double-blind, placebo-controlled clinical trial.
* Interventions:Therapeutic intervention and Pharmacist intervention.
* Number of participants = 120
* Number of groups = 4 groups each of 30 patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Neuropathies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Eligible patients assigned to either conventional hypoglycemic drugs without pharmaceutical care, or conventional hypoglycemic drugs accompanied with pharmacist interventions or patients will receive resveratrol 500 mg capsules orally once daily with their regular hypoglycemic drugs or resveratrol 500 mg capsule orally along with their regular hypoglycemic drugs for a period of three months, accompanied with pharmacist interventions.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

A prospective triple blind randomized clinical trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Resveratrol

Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months.

Group Type ACTIVE_COMPARATOR

Resveratrol

Intervention Type DRUG

This group received resveratrol with the conventional therapy

Placebo

Non-interventional group, participants are receiving only Placebo once daily for 3 months.

Placebo formulated as capsule match the color and size of the active comparator,

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

This group received placebo with the conventional therapy

Resveratrol plus Pharmaceutical care

Interventional group, participants in this group are receiving Resveratrol 500mg capsule once daily for 3 months with pharmaceutical care.

Group Type OTHER

Resveratrol plus Pharmaceutical care

Intervention Type OTHER

This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy

Placebo with pharmaceutical care

Interventional group, participants are receiving placebo along with pharmaceutical care for 3 months.

Group Type OTHER

Placebo+Pharmaceutical care

Intervention Type OTHER

This group received placebo with Pharmaceutical care in addition to the conventional therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resveratrol

This group received resveratrol with the conventional therapy

Intervention Type DRUG

Placebo

This group received placebo with the conventional therapy

Intervention Type DRUG

Resveratrol plus Pharmaceutical care

This group received Resveratrol with Pharmaceutical care in addition to the conventional therapy

Intervention Type OTHER

Placebo+Pharmaceutical care

This group received placebo with Pharmaceutical care in addition to the conventional therapy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pain due to bilateral peripheral neuropathy caused by type 2 diabetes mellitus.
* HbA1c of greater than 7%
* The daily pain must be present for at least 6 months, and the diagnosis will be confirmed by a score \>4 on the Michigan Neuropathy Screening Instrument (MNSI), Douleur Neuropathique 4 (DN4). The severity of pain when evaluated for the past 24 was ≥4 on the 10 cm Visual Analogue Scale (VAS) at baseline without the use of analgesic for 48 hours.

Exclusion Criteria

* Older subjects with high risks of cardiovascular diseases,
* Pregnant or breastfeeding,
* Having a prior renal transplant or current renal dialysis,
* Patients have a diagnosis of major depressive disorder, generalized anxiety disorder, heavy alcohol drinkers,
* Significant hepatic or renal disease,
* Patients on antioxidant therapy, or pentoxyphylline within the last month.

Minimum Eligible Age

50 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No